A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
Inclusion Criteria:
Exclusion Criteria:
global-roche-genentech-trials@gene.com888-662-6728 (U.S. Only)
Buenos Aires, Ciudad Autónoma de BuenosAires C1113AAE, Argentina
Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
San Juan, J5400DIL, Argentina
Viedma Rio Negro, R8500ACE, Argentina
Haine-Saint-Paul, 7100, Belgium
Porto Alegre, Rio Grande do Sul 90050-170, Brazil
São Paulo, São Paulo 01317-001, Brazil
Luoyang, 471003, China
Wuhan, 430022, China
Bogota, D.C., 110131, Colombia
Freiburg im Breisgau, 79110, Germany
München, 80336, Germany
Münster, 48145, Germany
Mumbai, Maharashtra 400004, India
NEW Delhi Delhi, National Capital Territory of Delhi 110092, India
Verona, Veneto 37124, Italy
Guadalajara, Jalisco 44280, Mexico
Mexico City, Mexico CITY (federal District) 06700, Mexico
Gda?sk, 80-214, Poland
Taoyuan County, 333, Taiwan
Bakirkoy / Istanbul, 34147, Turkey (Türkiye)
Sihhiye/Ankara, 06230, Turkey (Türkiye)